Clinical Trial Update: Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II study evaluating the combination of alectinib and bevacizumab in ALK-positive non-small cell lung cancer was terminated, with results posted in May…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alecensa (alectinib)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Non-Small Cell Lung Cancer (NSCLC) | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-05-13